{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:47:24Z","timestamp":1793890044700,"version":"4.8.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Pneumonia is a frequent and feared complication in intubated critically ill patients. Tissue concentrations of antimicrobial drugs need to be sufficiently high to treat the infection and also prevent development of bacterial resistance. It is uncertain whether pulmonary inflammation and injury affect antimicrobial drug penetration into lung tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine and compare tissue and BAL fluid concentrations of ceftaroline fosamil and linezolid in a model of unilateral acute lung injury in pigs and to evaluate whether dose adjustment is necessary to reach sufficient antimicrobial concentrations in injured lung tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After induction of unilateral acute lung injury, ceftaroline fosamil and linezolid were administered intravenously. Drug concentrations were measured in lung tissue through microdialysis and in blood and BAL fluid samples during the following 8\u2009hours. The primary endpoint was the tissue concentration area under the concentration curve in the first 8\u2009hours (AUC0\u20138\u2009h) of the two antimicrobial drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>In 10 pigs, antimicrobial drug concentrations were higher in inflamed and injured lung tissue compared with those in uninflamed and uninjured lung tissue (median ceftaroline fosamil AUC0\u20138\u2009h[and interquartile range]\u2009=\u200926.7\u2009mg\u2009\u00b7\u2009h\u2009\u00b7\u2009L\u22121 [19.7\u201339.0] vs. 16.0\u2009mg\u2009\u00b7\u2009h\u2009\u00b7\u2009L\u22121 [13.6\u201319.9], P\u2009=\u20090.02; median linezolid AUC0\u20138\u2009h 76.0\u2009mg\u2009\u00b7\u2009h\u2009\u00b7\u2009L\u22121 [68.1\u201396.0] vs. 54.6\u2009mg\u2009\u00b7\u2009h\u2009\u00b7\u2009L\u22121 [42.7\u201360.9], P\u2009=\u20090.01), resulting in a longer time above the minimal inhibitory concentration and in higher peak concentrations and dialysate\/plasma ratios. Penetration into BAL fluid was excellent for both antimicrobials, but without left-to-right differences (ceftaroline fosamil, P\u2009=\u20090.78; linezolid, P\u2009=\u20091.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tissue penetration of two commonly used antimicrobial drugs for pneumonia is enhanced by early lung tissue inflammation and injury, resulting in longer times above the minimal inhibitory concentration. Thus, lung tissue inflammation ameliorates antimicrobial drug penetration during the acute phase.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202306-0974oc","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T09:55:57Z","timestamp":1702634157000},"page":"829-839","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":11,"title":["Antimicrobial Drug Penetration Is Enhanced by Lung Tissue Inflammation and Injury"],"prefix":"10.1093","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-8039","authenticated-orcid":false,"given":"Johannes","family":"Geilen","sequence":"first","affiliation":[{"name":"Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Department of Anesthesia, General Intensive Care, and Pain Management"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kainz","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Department of Anesthesia, General Intensive Care, and Pain Management"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Zapletal","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Department of Anesthesia, General Intensive Care, and Pain Management"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Naka","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Department of Anesthesia, General Intensive Care, and Pain Management"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tichy","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Department of Anesthesia, General Intensive Care, and Pain Management"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"B\u00f6hmdorfer","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Clinical Pharmacokinetics\/Pharmacogenetics, and Imaging"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Department of Anesthesia, General Intensive Care, and Pain Management"},{"name":"Department of Intensive Care, Amsterdam University Medical Centers, location \u201cAMC\u201d, University of Amsterdam, Amsterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[{"name":"Institute of Outcomes Research, Center for Medical Data Science, and"},{"name":"Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8763-8215","authenticated-orcid":false,"given":"Valentin","family":"Ritschl","sequence":"additional","affiliation":[{"name":"Institute of Outcomes Research, Center for Medical Data Science, and"},{"name":"Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Geleff","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-2266","authenticated-orcid":false,"given":"Edda","family":"Tschernko","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, Department of Anesthesia, General Intensive Care, and Pain Management"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"2026012204274039800_bib1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMra1608077","article-title":"Acute respiratory distress syndrome","volume":"377","author":"Thompson","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012204274039800_bib2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.2017.21907","article-title":"Acute respiratory distress syndrome: advances in diagnosis and treatment","volume":"319","author":"Fan","year":"2018","journal-title":"JAMA"},{"key":"2026012204274039800_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00134-020-05980-0","article-title":"Ventilator-associated pneumonia in adults: a narrative review","volume":"46","author":"Papazian","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026012204274039800_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1164\/rccm.202204-0799ED","article-title":"What COVID-19 has taught us: ventilator-associated pneumonia is back!","volume":"206","author":"Niederman","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204274039800_bib5","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012204274039800_bib6","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026012204274039800_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1164\/rccm.201607-1447ED","article-title":"The 2016 guidelines for hospital-acquired and ventilator-associated pneumonia","volume":"195","author":"Govindan","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204274039800_bib8","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s00134-020-06292-z","article-title":"Pulmonary infections complicating ARDS","volume":"46","author":"Luyt","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026012204274039800_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/21548331.2015.1037228","article-title":"Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"43","author":"Kaye","year":"2015","journal-title":"Hosp Pract (1995)"},{"key":"2026012204274039800_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12931-018-0905-x","article-title":"Efficacy and effectiveness of ceftaroline fosamil in patients with pneumonia: a systematic review and meta-analysis","volume":"19","author":"Sotgiu","year":"2018","journal-title":"Respir Res"},{"key":"2026012204274039800_bib11","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated Gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","volume":"73","author":"Wunderink","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026012204274039800_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3949\/ccjm.87a.19117","article-title":"Hospital-acquired and ventilator-associated pneumonia: diagnosis, management, and prevention","volume":"87","author":"Modi","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"2026012204274039800_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society; Infectious Diseases Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204274039800_bib14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/jac\/dks022","article-title":"Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia","volume":"67","author":"Boselli","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib15","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1093\/jac\/dkac299","article-title":"Population pharmacokinetic\/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance","volume":"77","author":"Chauzy","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12967-022-03753-5","article-title":"Unilateral acute lung injury in pig: a promising animal model","volume":"20","author":"Geilen","year":"2022","journal-title":"J Transl Med"},{"key":"2026012204274039800_bib17","author":"Geilen","year":"2023"},{"key":"2026012204274039800_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2146\/ajhp160006","article-title":"Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"74","author":"White","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"2026012204274039800_bib19","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1128\/AAC.00356-16","article-title":"Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients","volume":"60","author":"Taubert","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib20","doi-asserted-by":"crossref","first-page":"e0067921","DOI":"10.1128\/AAC.00679-21","article-title":"Plasma and lung tissue pharmacokinetics of ceftaroline fosamil in patients undergoing cardiac surgery with cardiopulmonary bypass: an in vivo microdialysis study","volume":"65","author":"Edlinger-Stanger","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.CCM.0000168206.59873.80","article-title":"Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"2026012204274039800_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1986","journal-title":"J Appl Physiol (1985)"},{"key":"2026012204274039800_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2288-2-15","article-title":"Choosing marginal or random-effects models for longitudinal binary responses: application to self-reported disability among older persons","volume":"2","author":"Carri\u00e8re","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"2026012204274039800_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1165\/rcmb.2009-0210ST","article-title":"An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals","volume":"44","author":"Matute-Bello","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204274039800_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.2016.1170807","article-title":"Pharmacokinetics of linezolid in critically ill patients","volume":"12","author":"Sazdanovic","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026012204274039800_bib26","doi-asserted-by":"crossref","first-page":"e0074122","DOI":"10.1128\/aac.00741-22","article-title":"Population pharmacokinetic modeling and probability of target attainment of ceftaroline in brain and soft tissues","volume":"66","author":"Helfer","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib27","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1128\/AAC.36.6.1171","article-title":"Pulmonary disposition of antimicrobial agents: methodological considerations","volume":"36","author":"Baldwin","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib28","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1128\/AAC.01468-05","article-title":"Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis","volume":"50","author":"Buerger","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib29","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1128\/AAC.01078-12","article-title":"Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model","volume":"56","author":"Bhalodi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib30","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib31","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1128\/AAC.00498-15","article-title":"Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects","volume":"59","author":"Justo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/jcph.2031","article-title":"Pharmacokinetic\/pharmacodynamic parameters of linezolid in the epithelial lining fluid of patients with sepsis","volume":"62","author":"Wu","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2026012204274039800_bib33","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jcph.153","article-title":"Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"53","author":"Van Wart","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2026012204274039800_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13054-023-04512-8","article-title":"A long-lasting porcine model of ARDS caused by pneumonia and ventilator-induced lung injury","volume":"27","author":"Barbeta","year":"2023","journal-title":"Crit Care"},{"key":"2026012204274039800_bib35","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib36","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/AAC.48.6.2228-2232.2004","article-title":"Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis","volume":"48","author":"Tomaselli","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2125.2003.01797.x","article-title":"Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis","volume":"55","author":"Tomaselli","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"2026012204274039800_bib38","doi-asserted-by":"crossref","first-page":"e0156421","DOI":"10.1128\/AAC.01564-21","article-title":"Target site pharmacokinetics of meropenem: measurement in human explanted lung tissue by bronchoalveolar lavage, microdialysis, and homogenized lung tissue","volume":"65","author":"Paal","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jac\/dkq413","article-title":"High extracellular levels of cefpirome in unaffected and infected lung tissue of patients","volume":"66","author":"Lindenmann","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/ajrccm.165.2.2106082","article-title":"Closed-chest microdialysis to measure antibiotic penetration into human lung tissue","volume":"165","author":"Herkner","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204274039800_bib41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1185\/03007990903512057","article-title":"The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid","volume":"26","author":"Stein","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2026012204274039800_bib42","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/491714","article-title":"The role of vancomycin in the treatment paradigm","volume":"42","author":"Stevens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026012204274039800_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkl429","article-title":"The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus","volume":"59","author":"Goldstein","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1164\/rccm.201711-2259LE","article-title":"Lung ultrasound and microbubbles enhance aminoglycoside efficacy and delivery to the lung in Escherichia coli-induced pneumonia and acute respiratory distress syndrome","volume":"198","author":"Sugiyama","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204274039800_bib45","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkm431","article-title":"Effect of severity of sepsis on tissue concentrations of linezolid","volume":"61","author":"Thallinger","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib47","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib48","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"Honeybourne","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026012204274039800_bib49","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects","volume":"60","author":"Riccobene","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204274039800_bib50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13054-023-04331-x","article-title":"Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia","volume":"27","author":"Motos","year":"2023","journal-title":"Crit Care"},{"key":"2026012204274039800_bib51","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s00134-004-2428-9","article-title":"Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness","volume":"30","author":"Mehrotra","year":"2004","journal-title":"Intensive Care Med"},{"key":"2026012204274039800_bib52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/ph15040463","article-title":"Microbiological, clinical, and PK\/PD features of the new anti-Gram-negative antibiotics: \u03b2-lactam\/\u03b2-lactamase inhibitors in combination and cefiderocol\u2014an all-inclusive guide for clinicians","volume":"15","author":"Principe","year":"2022","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/7\/829\/66426447\/ajrccm_209_7_829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/7\/829\/66426447\/ajrccm_209_7_829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:27:54Z","timestamp":1769074074000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/209\/7\/829\/8426999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202306-0974oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2023-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}